177Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer

Biomedicines

卷:9

RathanM. Subramaniam¹  DuyguHas Simsek²  Yasemin Sanli²  AyseTuba Kendi³  Oner Sanli⁴ 

[1] Dean’s Office, Otago Medical School, University of Otago, Dunedin 9054, New Zealand;

[2] Department of Nuclear Medicine, Istanbul Faculty of Medicine, Istanbul University,34093 Istanbul, Turkey;

[3] Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA;

[4] Department of Urology, Istanbul Faculty of Medicine, Istanbul University, 34093 Istanbul, Turkey;

关键词: CRPC;    ¹⁷⁷Lu-PSMA;    PSA;    prostate cancer;    metastasis;   

DOI  :  10.3390/biomedicines9040430

来源: DOAJ

【 摘 要 】

The aim of this narrative review is to evaluate the current status of ¹⁷⁷Lu-PSMA (prostate specific membrane antigen) therapy for metastatic castration-resistant prostate cancer (mCRPC) in the light of the current literature. We also addressed patient preparation, therapy administration and side effect profiles. ¹⁷⁷Lu-PSMA therapy efficacy was assessed by using prospective trials, meta-analyses and major retrospective trials. Predictors of efficacy were also mentioned. Although there are some different approaches regarding the use of ¹⁷⁷Lu-PSMA therapy in different countries, this type of therapy is generally safe, with a low toxicity profile. From the oncological point of view, a PSA (prostate specific antigen) decline of ≥50% was seen in 10.6–69% of patients with mCRPC; whereas progression-free survival (PFS) was reported to be 3–13.7 months in different studies. Consequently, ¹⁷⁷Lu-PSMA therapy is a promising treatment in patients with mCRPC, with good clinical efficacy, even in heavily pretreated patients with multiple lines of systemic therapy. Currently, there are ongoing clinical trials in the United States, including a phase III multicenter FDA registration trial.

【 授权许可】

Unknown